Bacteriophages 2015

London, London
Tuesday, 27 January 2015

This event will be held at The O2,  a large entertainment district on the Greenwich peninsula in South East London, England.
Bacteriophages 2015
Tuesday, 27 January 2015 09:00 -
Thursday, 29 January 2015 17:00

Cineworld: The O2
Peninsula Square
London
London
SE10 0DX
United Kingdom

Map and Directions

This event will discuss the many roles of bacteriophages, ranging from fundamental biological research to their use in medical and industrial biotechnologies.  Topics will include  uses of phages for therapeutics, food manufacture, delivery vectors, drivers of microbiota structure reporters of microbiome diversity, and their  role on the environment 

This event  has CPD accreditation and an open oral and poster session.  Abstracts can be submitted on any subject related to Bacteriophages

The Deadline for abstract submissions for oral presentation is Oct10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the event
.
You can download the instructions for authors at 

www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf

Hashtag: #Phage2015

Talks include
European Implementation of Bacteriophage Therapy: Impact of Medicinal Product Legislation on Tailored Hospital Care
Gilbert Verbeken, Queen Astrid Military Hospital, Burn Wound Centre, Brussels, Belgium

Regulation of replication of Shiga toxin-converting bacteriophages
Professor Grzegorz Wegrzyn, Department of Molecular Biology, University of Gdansk, Poland

Bacteriophages for healthy living 
Dr Alexander Sulakvelidze, Intralytix, Inc, Baltimore, USA

Phage recombination
Dr Gary Sharpless, Fellow of the Wolfson Research Institute for Health and Wellbeing, Visiting Senior Lecturer in the Department of Chemistry, Senior Lecturer in the School of Biological and Biomedical Sciences, Durham University, UK

Recognition is the first step - harnessing phage-host interaction for rapid diagnostics
Professor. Dr. Martin J. Loessner, ETH Zurich, Institute of Food, Nutrition and Health, Schmelzbergstrasse 7, Zurich, Switzerland

GMP manufacture of phages for clinical trial
Tony Hitchcock, Technology Director, Cobra Biologics

Overview on Yersinia phages and update on phage therapy initiative in Finland
Professor Mikael Skurnik, Ph.D., Professor of Bacteriology, Haartman Institute, Department of Bacteriology and Immunology, Research Programs Unit, Immunobiology, Helsinki University Central Hospital Laboratory Diagnostics, Finland


Stx prophage control of host phenotypes
Dr. Heather E. Allison, University of Liverpool, BioSciences Building, Crown Street, Liverpool, United Kingdom

Bacteriophage lytic enzymes with a broad antibacterial spectrum
Dr Magdalena Plotka, Department of Microbiology, University of Gdansk, Poland, Department of Microbiology, University of Gdansk, Gdansk, Poland

Leveraging bacteriophages for high speed, enrichment-free environmental monitoring
Dr Michael Koeris, Founder, VP Business Development & Operations, Sample6, Inc, Boston, US

Atomic structure of Bordetella phage BPP1 reveals a new topology of the highly conserved HK97-like fold
Professor Z. Hong Zhou, Ph.D., Electron Imaging Center for Nanomachines (EICN), CNSI and Dept of Microbiology, Immun. & Mol. Genetics, UCLA, Los Angeles, CA, USA

Novel polymerases from marine phages
Dr Bin Zhu, Boston, MA, USA

Phage therapy in a post antibiotic era: The savior of the human race or a pie in the sky?
Professor. Robert R. Bragg, Dept. of Microbial, Biochemical & Food Biotechnology, Faculty of Natural and Agricultural Sciences, University of the Free State, Bloemfontein, South Africa

Extensive bacteriophage mediated horizontal gene transfer during Staphylococcus aureus colonization in vivo
Dr Jodi A Lindsay, PhD, St George's, University of London, London, UK

Modern ideas for combating bacteria
Dr Zuzanna Drulis-Kawa PhD., Institute of Genetics and Microbiology, University of Wroclaw, Poland

Control of recombination directionality by serine integrases
Dr Paul CM Fogg, University of York, Department of Biology, Wentworth Way, York, UK

Developing bacteriophage-based products for bio-control of unwanted bacteria in foodstuffs, animal health and human applications - possibilities and challenges
Dr Steven Hagens, PhD, Chief Scientific Officer, The Netherlands

Crystal structures of the Fibre Proteins of Bacteriophage T4, T5 and T7
Dr Mark van Raaij, Centro Nacional de Biotecnologia-CSIC, Madrid, Spain

Translating Bacteriophage and Lytic enzymes to uses for control of bacteria in environmental, human and animal applications
Dr David P Trudil, NHDetect Corp & Eliava Institute of Bacteriophage, Reisterstown, MD, USA

Working Collaboratively To Jump-Start Phage Therapy
Dr. Elizabeth Martin Kutter, Lab I, The Evergreen State College, Olympia, WA, USA

Ecology, evolution and applications of bacteriophages in bacterial pathogens with environmental reservoirs
Dr Martha Clokie, Reader in Microbiology, Department of Infection, Immunity and Inflammation, Medical Sciences Building, University of Leicester

TBC
Dr Aidan Coffey, Cork Institute of Technology, Ireland

Confirmed Speakers Include

Professor Stephane Evoy, University of Alberta, Canada
Professor Louise Temple, James Madison University, Harrisonburg, Virginia, USA

Keywords:  Abortive, Infection, Bacteriophage, Resistance,Toxin ,Purification Monolith,Yield ,Scaleable, cGMP, clinical 
trials, regulation, FDA, EMA, therapeutic use, lung, infection, Campylobacter, phage therapy, poultry, biofilms, Clostridium difficile, bacteriophages, genomes, diagnostic, therapeutic, Metagenomics, ecology, microbial functioning, 
bacteriophages, Genomics, Metabolism, Clostridium difficile, Pseudomonas aeruginosa, gastrointestine, Bacteriophage, gene delivery, targeted gene therapy,phage nanobiotechnology, genetic recombination, branched DNA, endonucleases, Science education, host-range, lysis, Bacillus phages, Bacteriophage, Yersinia pestis, Yersinia enterocolitica, phage receptor, lipopolysaccharide, Diagnostic, Food Safety, Synthetic Biology, endolysins, thermostability, antibacterial agents, Marine phage, polymerase, RNA, DNA, molecular reagents, Therapy, antibiotics, enzymes, expression, phages, salmonellosis, colibacillosis, chickens, Phage, GMP, clincial trials, Shiga toxin, phage regulator, RNA Seq, lysogen, phenotype conversion, Horizontal gene transfer, transduction, colonization, Staphylococcus aureus, Endolysin, tail fibre, cell wall teichoic acid, cell wall binding, antimicrobials, alternative therapies, bacteriophages, phage-derived proteins, Bacteriophage, Bacteriophage Therapy, Advanced Therapy, Regulatory, Hospital Exemption, Serine, Integrase, RDF, recombination, excisionase, Clostridium difficile, bacteriophage, lysogenic, endolysin, antimicrobials, Fibre proteins, X-ray crystallography, site-directed mutagenesis, phage therapy, diabetic ulcers, staph, Chromatography, purification, Translational, SRB, Detection, Bacteriophage, Lytic Enzymes, Bio-control, Target Pathogens

 

Contact Details

Payment Instructions

  • Payment must be received prior to the meeting

    Credit card
    You can pay during your online registration using your credit card. The information taken will be by secure server. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered 

    Paypal
    You can either use your Paypal account or click on the no account link to pay directly by credit or debit card

    If you wish to pay by purchase order or bank transfer, please contact sales@euroscicon.com

        Linked in   
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5 4LQ. 


© 2016
Quick, easy and affordable online event registration and event management software for all event sizes.